Sous embargo indéterminé.
Version: Final published version
Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Revue Médicale Suisse
Progress in the understanding of the hepatitis C virus life cycle allowed the development of new, very promising antiviral therapies. Although these new drugs have a favourable profile in terms of efficacy, tolerance and interaction potential, their prescription in the setting of comedication and impaired renal or hepatic function remains a challenge. Here, we provide a summary of pharmacological considerations, focusing on sofosbuvir, simeprevir and daclatasvir. A better understanding of their metabolic pathways and transporters may help the prescriber to identify and manage drug interactions especially in patients under immunosuppressive or anti-HIV therapy. Recommendations for the prescription of these drugs in specific situations are also discussed.
Antiviral Agents/pharmacology, Antiviral Agents/therapeutic use, Drug Interactions, Hepatitis C, Chronic/drug therapy, Heterocyclic Compounds, 3-Ring/pharmacology, Heterocyclic Compounds, 3-Ring/therapeutic use, Humans, Imidazoles/pharmacology, Imidazoles/therapeutic use, Protease Inhibitors/pharmacology, Protease Inhibitors/therapeutic use, Sulfonamides/pharmacology, Sulfonamides/therapeutic use, Uridine Monophosphate/analogs & derivatives, Uridine Monophosphate/pharmacology, Viral Nonstructural Proteins/antagonists & inhibitors
Last modification date